Representatives will set up a local presence in Boston.

Global Care Initiative (GCI), a consortium of five leading non-profit French research institutes, today announces that it will have a representative in the US, in Boston, Massachusetts. This new presence in Boston will provide better accessibility to American partners. Global Care combines strong skillsets, recognized IP and unique technology platforms in their offering. The consortium functions as a one-stop shop to life sciences companies and research organizations that seek effective R&D partnerships.
 
The consortium is currently running over 200 overseas contracts in oncology, infectious diseases, ophthalmology and neurology. Recent successes include the international phase III and registration for the blockbuster Rituximab (a chimeric monoclonal antibody with over USD 4 billion turnover in Lymphoma) and the creation of Fovea Pharmaceuticals, a spin-off of the Institut de la Vision, acquired by Sanofi in 2009. The scientists of the consortium were also involved in the first discovery of HIV 1 and 2 and the first development of associated diagnostic tests for HIV.
 
Global Care has extensive partnership experience with major US pharmaceutical, biotech and medtech companies, including Pfizer and Bio-Rad. It has lead on a wide range of innovative projects, including the identification of biomarkers, vaccine and therapeutics development, and improvements in diagnostic and imagery tools.
 
The consortium provides support and expertise at any stage, from basic research right through to late clinical phases. It offers external access to European markets through international KOLs and a range of strategic hospitals and medical staff. Dedicated teams provide specific support on project management, R&D, legal and finance, as required.
 
“Our one-stop-shop approach makes us a first choice to address the three biggest markets in the biomedical field, namely oncology, infectious diseases and central nervous systems diseases, as well as to address unmet medical needs,” said Pascal Deschaseaux, general manager at CALYM. “Fields like lymphoma or ophthalmology are expanding quickly in a fast market. We work alongside international leaders in both of these sectors.”
 
“Our institutes have unique industrial experience in their specific fields; chemical medicine at the Institut Curie, the originator of the Curie therapy, large multicentric clinical trials at CALYM, medtech focus at the Institut de la Vision, imaging expertise at ICM and fast mobilization during public health crises for Institut Pasteur,” said Damien Salauze VP, business development and licensing at Institut Curie.
 
“All different but smarter together. We value a transversal approach to develop common standards and best practice. We also want both the industry and patients to benefit from our extensive biocollections and databases[1] said Alexis Genin, head of research and technology development at ICM.
 
“We are delighted to have a location in the US where the ever-expanding and innovative life sciences market matches our vision of great science in the service of public health,” said Jean-Philippe Arie, COO at Global Care. “Our facility in Boston will generate strong R&D collaborations with both the industry and RTOs. We would also like to attract new talent to our team.”
 
Jean-Philippe Arie will deliver an industry friendly credentials presentation at BIO in San Diego at 3:15pm on Wednesday, June 25. Jean-Philippe has the scientific and business expertise to complement the Global Care business operation in North America.

more about global care initiative